Bosutinib
A tyrosine kinase inhibitor that targets BCR-ABL and certain SRC kinases, used to treat chronic myelogenous leukemia in patients who have failed or are intolerant of prior therapies. By blocking the abnormal BCR-ABL protein, it slows the growth of leukemia cells. Gastrointestinal side effects are common, particularly early in treatment.
Peso Molecular
530,4000 g/mol
LogP
5,40
TPSA
82,90 Ų
Regra dos 5 de Lipinski
Reprovado
Áreas Terapêuticas
Mecanismo de Ação
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …
Estrutura 2D
Cite this structure
Embed this structure
SMILES
COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
InChI
InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
Molecular Formula
C26H29Cl2N5O3
HBD / HBA
1 / 8
Ligações Rotacionáveis
9
Átomos Pesados
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A tyrosine kinase inhibitor that targets BCR-ABL and certain SRC kinases, used to treat chronic myelogenous leukemia in patients who have failed or are intolerant of prior therapies. By blocking the abnormal BCR-ABL protein, it slows the growth of leukemia cells. Gastrointestinal side effects are common, particularly early in treatment.
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.
Yes, Bosutinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL288441. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5328940. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bosutinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bosutinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bosutinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bosutinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bosutinib"></drugfyi-drug>